This protocol addresses female patients with androgenetic alopecia and clinical or biochemical evidence of hyperandrogenism, in whom a prior course of topical minoxidil did not achieve the required treatment goals.
First-line therapy with topical minoxidil was assessed at 6 months. The required goals — stopping hair loss and inducing hair regrowth (increased hair count) — were not achieved. This inadequate response triggers escalation to the current protocol.
Prevention of further progression of androgenetic alopecia — specifically, halting ongoing hair loss.
DOI: 10.1111/jdv.14624
Oral CPA can be considered to prevent progression of AGA in women with clinical or biochemical evidence of hyperandrogenism.
Cyproterone acetate is generally prescribed in combination with an oestrogen as an oral contraceptive in oral contraceptive pills (2 mg over 21 days or added to an oral contraceptive on days 1–10 at 5–50 mg per day for enhanced anti-androgen activity).
As AGA is a naturally progressive disease, therapy can have two required outcomes, namely stop of hair loss and induction of hair regrowth.
View source ↗